ATTORNEY’S ON BOTH SIDES OF A SHAREHOLDER LAWSUIT AGAINST A BRISTOL BASED PHARMACEUTICAL COMPANY ARE REPORTEDLY READY TO SETTLE THE ISSUE. A JURY TRIAL WAS SET FOR LATER THIS MONTH, BUT THE OPPOSING PARTIES HAVE SUBMITTED A PROPOSAL THAT WOULD COMPEL KING PHARMACEUTICALS TO STRENGTHEN INTERAL GOVERNANCE CONTROLS AND PAY 13.5 MILLION TO THE PLAINTIFF’S ATTORNEYS. THE FIRST LAWSUIT WAS BROUGHT ON BEHALF OF KING SHAREHOLDERS WHO WERE CONCERNED OVER FAULTY ACCOUNTING METHODS THAT LED TO THE COMPANY MISSTATING ITS EARNINGS, SHORT CHANGING FEDERAL AND STATE GOVERNMENTS IN MEDICAID REBATES AND ERODING THE VALUE OF ITS STOCK. THE INDIVIDUAL DEFENDANTS HAVE DENIED ALL WRONGDOING. IN THE PROPOSED SETTLEMENT, THE OPPOSING PARTIES CITE BOTH MOUNTING LEGAL COSTS AND THE SUFFICIENCY OF NEW GOVERNANCE PROVISIONS THAT WOULD BENEFIT KING AS REASONS NOT TO GO TO TRIAL.